Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of…
Merck known as MSD outside the United States and Canada, and DNAtrix announced they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of…
Read More...
Read More...